Methylenetetrahydrofolate reductase (MTHFR) 677C>T and methionine synthase reductase (MTRR) 66A>G polymorphisms

Association with serum homocysteine and angiographic coronary artery disease in the era of flour products fortified with folic acid

Emmanouil S. Brilakis, Peter B. Berger, Karla V. Ballman, Rima Rozen

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

We analyzed the association between the methylenetetrahydrofolate reductase (MTHFR) 677C>T and methionine synthase reductase (MTRR) 66A>G polymorphisms with serum homocysteine and with coronary artery disease (CAD) in 504 patients undergoing clinically-indicated angiography between July 1998 and January 1999. Significant CAD (≥50% stenosis in ≥one artery, blinded to risk factors) was present in 271 patients (54%). Median homocysteine (μmol/l) was 8.8 (interquartile range: 7.5-10.7). The prevalence of the MTHFR TT, CT, and CC genotypes was 11, 44 and 45%, respectively. Median tHcy (with interquartile ranges) for the entire population was 8.8 (7.5-10.7), and for the TT, CT, and CC genotypes was 9.7 (8.2-11.4), 8.8 (7.5-10.7), and 8.6 (7.3-10.6) μmol/l, respectively (P=0.04). On multiple logistic regression analysis, the MTHFR TT genotype was associated with hyperhomocysteinemia (adjusted OR=3.57; 95% CI, 1.47-8.70), but not with significant CAD. The prevalence of the MTRR AA, AG, GG genotypes was 19, 50 and 31%, respectively. There were no differences in mean homocysteine, prevalence of hyperhomocysteinemia and significant CAD between the three genotypes. On multivariate analysis, the MTRR genotypes were not associated with serum homocysteine or with significant CAD.

Original languageEnglish (US)
Pages (from-to)315-322
Number of pages8
JournalAtherosclerosis
Volume168
Issue number2
DOIs
StatePublished - Jun 1 2003

Fingerprint

Methylenetetrahydrofolate Reductase (NADPH2)
Flour
Homocysteine
Folic Acid
Coronary Artery Disease
Genotype
Serum
Hyperhomocysteinemia
methionine synthase reductase
Angiography
Pathologic Constriction
Multivariate Analysis
Arteries
Logistic Models
Regression Analysis
Population

Keywords

  • Coronary artery disease
  • Gene polymorphism
  • Homocysteine
  • Methionine synthase reductase
  • Methylenetetrahydrofolate reductase
  • Risk factors

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{ba4fe3bee9f0433493f6a14197547eae,
title = "Methylenetetrahydrofolate reductase (MTHFR) 677C>T and methionine synthase reductase (MTRR) 66A>G polymorphisms: Association with serum homocysteine and angiographic coronary artery disease in the era of flour products fortified with folic acid",
abstract = "We analyzed the association between the methylenetetrahydrofolate reductase (MTHFR) 677C>T and methionine synthase reductase (MTRR) 66A>G polymorphisms with serum homocysteine and with coronary artery disease (CAD) in 504 patients undergoing clinically-indicated angiography between July 1998 and January 1999. Significant CAD (≥50{\%} stenosis in ≥one artery, blinded to risk factors) was present in 271 patients (54{\%}). Median homocysteine (μmol/l) was 8.8 (interquartile range: 7.5-10.7). The prevalence of the MTHFR TT, CT, and CC genotypes was 11, 44 and 45{\%}, respectively. Median tHcy (with interquartile ranges) for the entire population was 8.8 (7.5-10.7), and for the TT, CT, and CC genotypes was 9.7 (8.2-11.4), 8.8 (7.5-10.7), and 8.6 (7.3-10.6) μmol/l, respectively (P=0.04). On multiple logistic regression analysis, the MTHFR TT genotype was associated with hyperhomocysteinemia (adjusted OR=3.57; 95{\%} CI, 1.47-8.70), but not with significant CAD. The prevalence of the MTRR AA, AG, GG genotypes was 19, 50 and 31{\%}, respectively. There were no differences in mean homocysteine, prevalence of hyperhomocysteinemia and significant CAD between the three genotypes. On multivariate analysis, the MTRR genotypes were not associated with serum homocysteine or with significant CAD.",
keywords = "Coronary artery disease, Gene polymorphism, Homocysteine, Methionine synthase reductase, Methylenetetrahydrofolate reductase, Risk factors",
author = "Brilakis, {Emmanouil S.} and Berger, {Peter B.} and Ballman, {Karla V.} and Rima Rozen",
year = "2003",
month = "6",
day = "1",
doi = "10.1016/S0021-9150(03)00098-4",
language = "English (US)",
volume = "168",
pages = "315--322",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Methylenetetrahydrofolate reductase (MTHFR) 677C>T and methionine synthase reductase (MTRR) 66A>G polymorphisms

T2 - Association with serum homocysteine and angiographic coronary artery disease in the era of flour products fortified with folic acid

AU - Brilakis, Emmanouil S.

AU - Berger, Peter B.

AU - Ballman, Karla V.

AU - Rozen, Rima

PY - 2003/6/1

Y1 - 2003/6/1

N2 - We analyzed the association between the methylenetetrahydrofolate reductase (MTHFR) 677C>T and methionine synthase reductase (MTRR) 66A>G polymorphisms with serum homocysteine and with coronary artery disease (CAD) in 504 patients undergoing clinically-indicated angiography between July 1998 and January 1999. Significant CAD (≥50% stenosis in ≥one artery, blinded to risk factors) was present in 271 patients (54%). Median homocysteine (μmol/l) was 8.8 (interquartile range: 7.5-10.7). The prevalence of the MTHFR TT, CT, and CC genotypes was 11, 44 and 45%, respectively. Median tHcy (with interquartile ranges) for the entire population was 8.8 (7.5-10.7), and for the TT, CT, and CC genotypes was 9.7 (8.2-11.4), 8.8 (7.5-10.7), and 8.6 (7.3-10.6) μmol/l, respectively (P=0.04). On multiple logistic regression analysis, the MTHFR TT genotype was associated with hyperhomocysteinemia (adjusted OR=3.57; 95% CI, 1.47-8.70), but not with significant CAD. The prevalence of the MTRR AA, AG, GG genotypes was 19, 50 and 31%, respectively. There were no differences in mean homocysteine, prevalence of hyperhomocysteinemia and significant CAD between the three genotypes. On multivariate analysis, the MTRR genotypes were not associated with serum homocysteine or with significant CAD.

AB - We analyzed the association between the methylenetetrahydrofolate reductase (MTHFR) 677C>T and methionine synthase reductase (MTRR) 66A>G polymorphisms with serum homocysteine and with coronary artery disease (CAD) in 504 patients undergoing clinically-indicated angiography between July 1998 and January 1999. Significant CAD (≥50% stenosis in ≥one artery, blinded to risk factors) was present in 271 patients (54%). Median homocysteine (μmol/l) was 8.8 (interquartile range: 7.5-10.7). The prevalence of the MTHFR TT, CT, and CC genotypes was 11, 44 and 45%, respectively. Median tHcy (with interquartile ranges) for the entire population was 8.8 (7.5-10.7), and for the TT, CT, and CC genotypes was 9.7 (8.2-11.4), 8.8 (7.5-10.7), and 8.6 (7.3-10.6) μmol/l, respectively (P=0.04). On multiple logistic regression analysis, the MTHFR TT genotype was associated with hyperhomocysteinemia (adjusted OR=3.57; 95% CI, 1.47-8.70), but not with significant CAD. The prevalence of the MTRR AA, AG, GG genotypes was 19, 50 and 31%, respectively. There were no differences in mean homocysteine, prevalence of hyperhomocysteinemia and significant CAD between the three genotypes. On multivariate analysis, the MTRR genotypes were not associated with serum homocysteine or with significant CAD.

KW - Coronary artery disease

KW - Gene polymorphism

KW - Homocysteine

KW - Methionine synthase reductase

KW - Methylenetetrahydrofolate reductase

KW - Risk factors

UR - http://www.scopus.com/inward/record.url?scp=0037497943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037497943&partnerID=8YFLogxK

U2 - 10.1016/S0021-9150(03)00098-4

DO - 10.1016/S0021-9150(03)00098-4

M3 - Article

VL - 168

SP - 315

EP - 322

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 2

ER -